DrugPatentWatch Database Preview

Viiv Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for VIIV HLTHCARE, and when can generic versions of VIIV HLTHCARE drugs launch?

VIIV HLTHCARE has twenty approved drugs.

There are fourteen US patents protecting VIIV HLTHCARE drugs.

There are six hundred and seventy-two patent family members on VIIV HLTHCARE drugs in sixty-six countries and one hundred and forty-two supplementary protection certificates in sixteen countries.

Summary for Viiv Hlthcare

International Patents:	672
US Patents:	14
Tradenames:	13
Ingredients:	13
NDAs:	20

Drugs and US Patents for Viiv Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	LEXIVA	fosamprenavir calcium	TABLET;ORAL	021548-001	Oct 20, 2003	AB	RX	Yes	Yes	6,514,953*PED				Y
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790-003	Jun 9, 2016		RX	Yes	No	9,242,986		Y	Y
Viiv Hlthcare	EPIVIR	lamivudine	SOLUTION;ORAL	020596-001	Nov 17, 1995	AA	RX	Yes	Yes
Viiv Hlthcare	SELZENTRY	maraviroc	TABLET;ORAL	022128-004	Nov 4, 2016		RX	Yes	No	7,576,097			Y
Viiv Hlthcare	TIVICAY	dolutegravir sodium	TABLET;ORAL	204790-001	Aug 12, 2013		RX	Yes	Yes	8,129,385		Y	Y
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000	AB	RX	Yes	Yes

Expired US Patents for Viiv Hlthcare

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	RETROVIR	zidovudine	TABLET;ORAL	020518-001	Dec 19, 1995	4,818,538
Viiv Hlthcare	COMBIVIR	lamivudine; zidovudine	TABLET;ORAL	020857-001	Sep 26, 1997	4,828,838*PED
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000	5,034,394*PED
Viiv Hlthcare	RESCRIPTOR	delavirdine mesylate	TABLET;ORAL	020705-002	Jul 14, 1999	5,563,142
Viiv Hlthcare	RETROVIR	zidovudine	CAPSULE;ORAL	019655-001	Mar 19, 1987	4,837,208
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000	4,833,130

Paragraph IV (Patent) Challenges for VIIV HLTHCARE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Oral Solution	20 mg/ml		2012-12-27
	Tablets	150 mg/300 mg		2007-06-26
	Tablets	10 mg, 25 mg and 50 mg		2017-08-14
	Tablets	300 mg/150 mg/300 mg		2011-03-22
	Oral Solution	10 mg/mL		2011-11-22
	Tablets	300 mg		2009-01-28
	Tablets	700 mg		2012-01-18
	Tablets	600 mg/300 mg		2007-09-27
	Tablets	600 mg/50 mg/300 mg		2017-08-14
	Tablets	150 mg and 300 mg		2007-10-16
	Tablets	150 mg and 300 mg		2011-08-08

International Patents for Viiv Hlthcare Drugs

Country	Patent Number	Estimated Expiration
Taiwan	I483947
Morocco	26716
Germany	60142469
Austria	550074
Singapore	155885
Austria	516026

Supplementary Protection Certificates for Viiv Hlthcare Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1419152	CR 2012 00021	Denmark		PRODUCT NAME: KOMBINATION AF RILPIVIRIN ELLER ET FARMACEUTISK ACCEPTABELT ADDITIONSSALT AF RILPIVIRIN, HERUNDER HYDROCHLORID ADDITIONSSALTET AF RILPIVIRIN, OG TENOFOVIR, NAVNLIG TENOFOVIRDISOPROXILFUMARAT; REG. NO/DATE: EU/1/11/737/001-002 20111128
0513917	98C0020	Belgium		PRODUCT NAME: LAMIVUDINE/ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001 19980318
1663240	PA2015038	Lithuania		PRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28, EU/1/11/737/002 20111128
1874117	517	Finland
1419152	C300529	Netherlands		PRODUCT NAME: RILPIVIRINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ADDITIEZOUT, IN HET BIJZONDER HET HYDROCHLORIDEZOUT; REGISTRATION NO/DATE: EU/1/11/736/001 20111128
1284974	PA 2008 004, C 1284974	Lithuania		PRODUCT NAME: MARAVIROCUM; REGISTRATION NO/DATE: EU/1/07/418/001 - EU/1/07/418/010, 20070918

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Viiv Hlthcare